Nevertheless, we found that knocking down ELK1 effectively reduces APP amyloidogenic processing by decreasing PS1 protein levels, whereas ELK1 overexpression does not alter PS1 levels in AD (Figs. 2 and 4). The gene discussed is APP; the disease is Alzheimer disease.